Join NFCR and Dr. Sujuan Ba in Discussion about All Things Cancer
Each episode of All Things Cancer will spotlight the most pressing topics in oncology, from cutting-edge treatments and emerging research to personal stories of resilience and hope. More than just a podcast, it’s a platform for raising awareness, advancing cancer education, and fostering a global community of support and collaboration.
Cancer impacts everyone—whether you’re a patient, caregiver, advocate, or researcher — This podcast delivers invaluable insights from those on the frontlines of the fight against it.
Subscribe now to stay up to date on the latest episodes and join the conversation shaping the future of cancer research.
LISTEN NOW:
Latest Episodes of All Things Cancer
Episode #19:
FEATURING: Dr. Tony Hunter on the Accidental Discovery that Changed Cancer Treatment
While studying tumor viruses at the Salk Institute, Dr. Hunter discovered tyrosine phosphorylation — a process by which rogue enzymes drive abnormal cell growth. It was an accidental finding that quietly set off a revolution. Today, it underpins more than 80 FDA-approved cancer drugs, including the landmark therapy Gleevec.
Listen Now On: Spotify | Apple | Youtube | Amazon Music
Episode #18:
What If You Could Know Your Breast Cancer Risk at 25? with Dr. Funmi Olopade
In this episode of All Things Cancer, guest host Hali Hartmann sits down with Dr. Funmi Olopade, a pioneering oncologist and professor at the University of Chicago, to explore the future of breast cancer prevention, detection, and treatment. Dr. Olopade shares what drew her to breast cancer research — inspired by colleagues and mentors who were unlocking the genetic roots of cancer — and explains how her thinking has evolved from treatment to prevention.
Listen Now On: Spotify | Apple Podcasts | YouTube | Amazon Music
Episode #17:
FEATURING: Kathy Giusti, founder of the Multiple Myeloma Research Foundation
In conversation with Dr. Sujuan Ba. Kathy talks through her diagnosis at 37, how that urgency drove her to build the MMRF, and the collaborative funding model she created that brought together pharma, academia, and the FDA to accelerate drug development — without claiming any IP.
